PMID- 30225230
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2222-3959 (Print)
IS  - 2227-4898 (Electronic)
IS  - 2222-3959 (Linking)
VI  - 11
IP  - 9
DP  - 2018
TI  - Comparison of one and three initial monthly intravitreal ranibizumab injection in 
      patients with macular edema secondary to branch retinal vein occlusion.
PG  - 1534-1538
LID - 10.18240/ijo.2018.09.17 [doi]
AB  - AIM: To compare three initial monthly intravitreal ranibizumab (IVR) injections 
      followed by pro re nata (PRN) dosing with one initial monthly IVR injections 
      followed by PRN dosing for macular edema (ME) secondary to branch retinal vein 
      occlusion (BRVO). METHODS: Forty-two eyes of 42 patients who had IVR injections 
      for BRVO were retrospectively studied. Eighteen eyes received 1 initial IVR 
      injection (1+PRN group) and 24 eyes received 3 monthly IVR injections (3+PRN). At 
      1, 3, 6 and 12mo; spectral-domain optical coherence tomography (SD-OCT) was 
      performed. Central macular thickness (CMT), the integrity of the external 
      limiting membrane (ELM), the presence of subretinal fluid, cyst size, the 
      presence of inner segment/outer segment (IS/OS) defect were determined. RESULTS: 
      At baseline the mean CMT was 521.3+/-153.2 microm in the 3+PRN group while it was 
      438.1+/-162.4 microm in 1+PRN group. At the final visit, mean CMT was 278.3+/-87.8 microm in 
      the 3+PRN group and 285.2+/-74.2 microm in the 1+PRN group (P=0.079). The changes in 
      CMT over the entire study period were also comparable in both groups (243+/-160 microm 
      in the 3+PRN group, and 152.9+/-175.3 microm in the 1+PRN group; P=0.090). At baseline, 
      best-corrected visual acuity (BCVA) was 0.92+/-0.60 logarithm of the minimal angle 
      of resolution (logMAR) in the 3+PRN group, while it was 0.72+/-0.46 logMAR in the 
      1+PRN group. Final BCVA was 0.42+/-0.55 logMAR in the 3+PRN group and 0.38+/-0.50 
      logMAR in the 1+PRN group (P=0.979). Additionally, the BCVA changes from baseline 
      to final visit were not significantly different (-0.50+/-0.45 logMAR in the 3+PRN 
      group, and -0.33+/-0.39 logMAR in the 1+PRN group; P=0.255). CONCLUSION: No 
      significant differences in the anatomical or functional results are found between 
      3+PRN and 1+PRN regimens in the patients receiving ranibizumab for ME secondary 
      to BRVO. Intact IS/OS and baseline BCVA are good predictor of the visual gain, 
      while baseline CMT is a good predictor of the anatomical gain.
FAU - Bayat, Alper Halil
AU  - Bayat AH
AD  - Departmant of Opthalmology, Okmeydani Research & Traning Hospital, Istanbul 
      34384, Turkey.
FAU - Cakir, Akin
AU  - Cakir A
AD  - Departmant of Opthalmology, Okmeydani Research & Traning Hospital, Istanbul 
      34384, Turkey.
FAU - Ozturan, Seyma Gulcenur
AU  - Ozturan SG
AD  - Departmant of Opthalmology, Okmeydani Research & Traning Hospital, Istanbul 
      34384, Turkey.
FAU - Bolukbasi, Selim
AU  - Bolukbasi S
AD  - Departmant of Opthalmology, Okmeydani Research & Traning Hospital, Istanbul 
      34384, Turkey.
FAU - Erden, Burak
AU  - Erden B
AD  - Departmant of Opthalmology, Okmeydani Research & Traning Hospital, Istanbul 
      34384, Turkey.
FAU - Elcioglu, Mustafa Nuri
AU  - Elcioglu MN
AD  - Departmant of Opthalmology, Okmeydani Research & Traning Hospital, Istanbul 
      34384, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20180918
PL  - China
TA  - Int J Ophthalmol
JT  - International journal of ophthalmology
JID - 101553860
PMC - PMC6133896
OTO - NOTNLM
OT  - branch retinal vein occlusion
OT  - macular edema
OT  - predictive factors
OT  - ranibizumab
OT  - therapy
EDAT- 2018/09/19 06:00
MHDA- 2018/09/19 06:01
PMCR- 2018/09/18
CRDT- 2018/09/19 06:00
PHST- 2017/10/11 00:00 [received]
PHST- 2018/04/23 00:00 [accepted]
PHST- 2018/09/19 06:00 [entrez]
PHST- 2018/09/19 06:00 [pubmed]
PHST- 2018/09/19 06:01 [medline]
PHST- 2018/09/18 00:00 [pmc-release]
AID - ijo-11-09-1534 [pii]
AID - 10.18240/ijo.2018.09.17 [doi]
PST - epublish
SO  - Int J Ophthalmol. 2018 Sep 18;11(9):1534-1538. doi: 10.18240/ijo.2018.09.17. 
      eCollection 2018.